Parkinson’s Disease – Landscape & Forecast – Disease Landscape & Forecast

Since 2015, ten new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon, including AbbVie’s ABBV-951, Amneal’s IPX203, and Addex’s dipraglurant. As developers seek to carve out a clinical role for each of these products, they will introduce additional complexity to a complicated treatment algorithm. New brands have the potential to meaningfully increase the market value, but intensifying competition, coupled with patient and payer cost-sensitivity in a crowded and mostly generic market, creates a challenging launch environment. Generic options are available in every PD drug class, and brands entering these classes will struggle to compete without decisive clinical differentiation. A deep understanding of current and future market dynamics in PD will be critical for new and established players vying for a share of this increasingly competitive landscape.

Questions Answered:

  • What will be the clinical and commercial impact of emerging levodopa reformulations (i.e., ABBV-951, ND-0612, IPX203)? Will they experience rapid uptake and alter the PD treatment paradigm, or will access hurdles and/or physician resistance limit their use?
  • How will neurologists differentiate between current and emerging adjunctive therapies for motor fluctuations and dyskinesia (e.g., amantadine vs. dipraglurant), and which will enjoy the greatest success in this highly generic market?
  • How will neurologists adopt the new acute rescue therapies for “off” periods, and what unmet needs remain for other novel therapies targeting motor symptoms in PD?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 25 country-specific interviews with thought-leading neurologists; supported by survey data collected for this and other Clarivate research.

Epidemiology: Total, diagnosed, and drug-treated prevalent cases of PD by country.

Emerging therapies: Phase II: 20 drugs; Phase III: 6 drugs; preregistration: 1 drug.

Market forecast features: Ten-year, annualized, drug-level sales and patient shares of key PD therapies through 2030, segmented by brands / generics.

Key companies: AbbVie, Acadia Pharmaceuticals, Acorda Therapeutics, Adamas Pharmaceuticals, Addex Therapeutics, Amneal Pharmaceuticals, Cerevel Therapeutics, Eisai, Hisamitsu Pharmaceutical, Kyowa Kirin, Meiji Seika Pharma, Mitsubishi Tanabe Pharma, Newron Pharmaceuticals, NeuroDerm, Osmotica Pharmaceuticals, Pharma Two B, Sumitomo Dainippon Pharma, Sunovion, Takeda, Teva, Theravance Biopharma, UCB, US WorldMeds, Zambon Pharma.

Key drugs: levodopa, amantadine, ampreloxetine, apomorphine, ABBV-951, AP-CD/LD, Duodopa / Duopa, dipraglurant, entacapone, Gocovri, Haruropi Tape, Inbrija, IPX203, Kynmobi, Lecigon, ND0612, Neupro, Nourianz, Nuplazid, Ongentys, Osmolex ER, pramipexole, P2B001, rasagiline, ropinirole, Rytary, selegiline, tavapadon, Trerief, Xadago.

Solution Enhancement

Disease Landscape & Forecast features continuous updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.

Table of contents

  • Parkinson's Disease - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • October 2021
      • Q3 2021
        • September 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
    • Key Findings
      • Parkinsons Disease - Key Findings - December 2021
        • June 2021
        • May 2021
        • April 2021
    • Market Outlook
      • Key Findings
        • Market Share of Drug Classes for Parkinson's Disease: 2020
        • Market Share of Drug Classes for Parkinson's Disease: 2030
        • Parkinson's Disease SWOT Analysis
      • COVID-19: Market Forecast Impact
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Parkinson's Disease?
          • What Factors Are Constraining the Market for Parkinson's Disease?
          • Major-Market Sales by Class in Parkinson's Disease: 2020-2030
          • Major-Market Patient Share by Class in Parkinson's Disease: 2020-2030
          • Total Sales by Region in Parkinson's Disease: 2020-2030
          • Major-Market Sales of Emerging Therapies in Parkinson's Disease: 2020-2030
          • Major-Market Sales of Key Current Brands in Parkinson's Disease: 2020-2030
        • Drug-Class-Specific Trends
          • Major-Market Sales of Key Dopamine Precursors in Parkinson's Disease: 2020-2030
          • U.S. Patient Share of Key Dopamine Precursors in Parkinson's Disease: 2020-2030
          • European Patient Share of Key Dopamine Precursors in Parkinson's Disease: 2020-2030
          • Major-Market Sales of Key Dopamine Agonists in Parkinson's Disease: 2020-2030
          • U.S. Patient Share of Key Dopamine Agonists in Parkinson's Disease: 2020-2030
          • Japanese Patient Share of Key Dopamine Agonists in Parkinson's Disease: 2020-2030
          • Major-Market Sales of MAO-B Inhibitors in Parkinson's Disease: 2020-2030
          • Major-Market Patient Share of MAO-B Inhibitors in Parkinson's Disease: 2020-2030
          • Major-Market Sales of COMT Inhibitors in Parkinson's Disease: 2020-2030
          • Major-Market Patient Share of COMT Inhibitors in Parkinson's Disease: 2020-2030
          • Major-Market Sales and Patient Share of Istradefylline in Parkinson's Disease: 2020-2030
          • Major-Market Sales of Key Antiglutamatergic Agents in Parkinson's Disease: 2020-2030
          • U.S. Patient Share of Antiglutamatergic Agents in Parkinson's Disease: 2020-2030
          • Major-Market Sales of Acute Rescue Therapies in Parkinson's Disease: 2020-2030
          • U.S. Patient Share of Acute Rescue Therapies in Parkinson's Disease: 2020-2030
          • Major-Market Sales of Antipsychotic Agents in Parkinson's Disease: 2020-2030
          • U.S. Patient Share of Antipsychotic Agents in Parkinson's Disease: 2020-2030
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Disease Overview
          • Etiology
            • Known and Suspected Nongenetic Risk and Protective Factors in Parkinson's Disease
            • Genetic Loci Linked to Familial and/or Sporadic Parkinson's Disease
          • Pathophysiology
            • Molecular and Cellular Processes Implicated in Neuronal Death in Parkinson's Disease
            • Brain Structures Implicated in Movement and Parkinson's Disease
            • Neuronal Circuits Within the Basal Ganglia Implicated in the Control of Normal Movement
            • Changes in Basal Ganglia Circuitry Following the Loss of Substantia Nigra Dopaminergic Neurons Leading to Motor Symptoms of Parkinson's Disease
            • Pathophysiological Processes and Mutant Genes Implicated in Parkinson's Disease
            • Role of Protein Folding and Degradation in Parkinson's Disease
            • Braak Staging System
          • Disease Progression
            • Progression of Clinical Symptoms Associated With Parkinson's Disease
          • Key Pathways and Drug Targets
            • Key Pathways and Drug Targets in Parkinson's Disease
        • Epidemiology
          • Key Findings
            • Epidemiology Populations
              • Disease Definition
              • Methods
              • Sources Used for Total Prevalent Cases of Parkinson's Disease
              • Total Prevalent Cases of Parkinson's Disease: 2020-2030 (Thousands)
              • Diagnosed Prevalent Cases of Parkinson's Disease: 2020-2030 (Thousands)
              • Drug-Treated Prevalent Cases of Parkinson's Disease: 2020-2030 (Thousands)
          • Current Treatment
            • Key Findings
              • Treatment Goals
                • Key Endpoints Used in Clinical Trials for Parkinson's Disease
              • Key Current Therapies
                • Overview
                • Mechanism of Action of Key Current Drug Classes Used for Parkinson's Disease
                • Mechanism of Action of Key Current Drug Classes Used for Parkinson's Disease
                • Current Treatments Used for Parkinson's Disease
                • Market Events Impacting the Use of Key Current Therapies in Parkinson's Disease
                • Advantages and Disadvantages of Dopamine Precursors
                • Expert Insight: Dopamine Precursors
                • Advantages and Disadvantages of Dopamine Agonists
                • Ongoing Clinical Development of the Apomorphine Pump
                • Expert Insight: Dopamine Agonists
                • Advantages and Disadvantages of MAO-B Inhibitors
                • Ongoing Clinical Development of Safinamide
                • Expert Insight: MAO-B Inhibitors
                • Advantages and Disadvantages of COMT Inhibitors
                • Expert Insight: COMT Inhibitors
                • Expert Insight: Lecigon
                • Advantages and Disadvantages of Istradefylline
                • Expert Insight: Adenosine A2A Receptor Antagonists
                • Advantages and Disadvantages of Antiglutamatergic Agents
                • Expert Insight: Antiglutamatergic Agents
                • Advantages and Disadvantages of Acute Rescue Therapies
                • Ongoing Clinical Development of Kynmobi
                • Expert Insight: Acute Rescue Therapies
                • Advantages and Disadvantages of Key Antidementia Agents
                • Expert Insight: Antidementia Agents
                • Advantages and Disadvantages of Antipsychotic Agents
                • Ongoing Clinical Development of Nuplazid
                • Expert Insight: Antipsychotic Agents
                • Advantages and Disadvantages of Other Agents
                • Ongoing Clinical Development of Droxidopa
                • Expert Insight: Other Agents
              • Medical Practice
                • Overview
                • Factors Influencing Drug Selection in Parkinson's Disease
                • Drug Selection in Parkinson's Disease by Disease Severity
                • Drug Selection in Parkinson's Disease for Select Nonmotor Symptoms
                • Treatment Decision Tree for Parkinson's Disease: United States
                • Treatment Decision Tree for Parkinson's Disease: Europe
                • Treatment Decision Tree for Parkinson's Disease: Japan
            • Unmet Need Overview
              • Current and Future Attainment of Unmet Needs in Parkinson's Disease
              • Top Unmet Needs in Parkinson's Disease: Current and Future Attainment
            • Emerging Therapies
              • Key Findings
                • Key Emerging Therapies
                  • Key Therapies in Late-Phase Development for Parkinson's Disease
                  • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Parkinson's Disease
                  • IPX203 Profile
                  • Analysis of the Clinical Development Program for IPX203
                  • Expert Insight: IPX203
                  • Expectations for Launch and Sales Opportunity of IPX203 in Parkinson's Disease
                  • ABBV-951 Profile
                  • Analysis of the Clinical Development Program for ABBV-951
                  • Expert Insight: ABBV-951
                  • Expectations for Launch and Sales Opportunity of ABBV-951 in Parkinson's Disease
                  • ND0612 Profile
                  • Analysis of the Clinical Development Program for ND0612
                  • Expert Insight: ND0612
                  • Expert Insight: Levodopa-Carbidopa Pump Therapies
                  • Expectations for Launch and Sales Opportunity of ND0612 in Parkinson's Disease
                  • P2B001 Profile
                  • Analysis of the Clinical Development Program for P2B001
                  • Expert Insight: P2B001
                  • Expectations for Launch and Sales Opportunity of P2B001 in Parkinson's Disease
                  • Tavapadon Profile
                  • Analysis of the Clinical Development Program for Tavapadon
                  • Expert Insight: Tavapadon
                  • Expectations for Launch and Sales Opportunity of Tavapadon in Parkinson's Disease
                  • Dipraglurant Profile
                  • Analysis of the Clinical Development Program for Dipraglurant
                  • Expert Insight: Dipraglurant
                  • Expectations for Launch and Sales Opportunity of Dipraglurant in Parkinson's Disease
                  • Ampreloxetine Profile
                  • Analysis of the Clinical Development Program for Ampreloxetine
                  • Expert Insight: Ampreloxetine
                  • Expectations for Launch and Sales Opportunity of Ampreloxetine in Parkinson's Disease
                • Early-Phase Pipeline Analysis
                  • Select Symptomatic Compounds in Phase II Development for the Motor Symptoms of Parkinson's Disease
                  • Select Symptomatic Compounds in Phase II Development for the Nonmotor Symptoms of Parkinson's Disease
                  • Select Disease-Modifying Compounds in Phase II Development for Parkinson's Disease
                  • Challenges to Developing Disease-Modifying Therapies for Parkinson's Disease
                  • Select Biomarker Studies and Initiatives for Parkinson's Disease
              • Access and Reimbursement Overview
                • Region-Specific Reimbursement Practices
                  • Key Market Access Considerations in Parkinson's Disease: United States
                  • General Reimbursement Environment: United States
                  • Key Market Access Considerations in Parkinson's Disease: EU5
                  • General Reimbursement Environment: EU5
                  • Key Market Access Considerations in Parkinson's Disease: Japan
                  • General Reimbursement Environment: Japan
              • Appendix
                • Parkinson's Disease Bibliography